Randomised trial of dobutamine versus placebo for low superior vena cava flow in preterm infants: Long‐term neurodevelopmental outcome.

Aim: Although circulatory impairment during the transitional circulation associates morbidity and mortality, its treatment remains controversial. In a pilot trial on circulatory impairment defined as low superior vena cava (SVC) flow, dobutamine (Db) versus placebo (PL) showed a trend towards improved short‐term outcomes. The purpose of this study was to report on the long‐term outcome of the infants who were observed for SVC flow patterns. Methods: Among the 126 infants <31 weeks of gestation prospectively scanned from birth, 28 presented low SVC flow within the first 24 h after birth and received Db (n = 16) or PL (n = 12). Follow‐up of survivors included motor assessment and Bayley Scales II or III at 2 years, and the Reynolds Intellectual Assessment Scale at 6 years. Neurodevelopmental impairment (NDI) was defined as: cerebral palsy (Gross Motor Function Classification System ≥ level 2), or a cognitive function score < −2 standard deviations; or moderate or severe hearing or visual impairment. Db group, PL group and normal‐flow group were compared. Results: Eighteen infants died (Db: 5; PL: 2; normal flow group: 11, P = 0.1). Follow‐up in survivors was accomplished in 80% and 55% of the cohort at 2 years and 6 years, respectively. No significant difference in the combined outcome (mortality or NDI) was found between the groups (42% Db, 36% PL, 30% normal flow group). Conclusions: This exploratory analysis did not show any differences in the long‐term outcome of infants according to SVC flow patterns or its treatment early after birth. [ABSTRACT FROM AUTHOR]